Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Yemen Health Report.
Press releases published on July 17, 2025
Gelteq Announces Agreement with IDT Australia to Secure Dedicated New Product Development and Manufacturing Facilities
GlobeNewswire
·
July 17, 2025
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company focused on developing and commercializing white label ingestible gel-based solutions for prescription drugs, nutraceuticals, pet …
Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships
GlobeNewswire
·
July 17, 2025
40+ year career at Roche founded on dedication to bringing new innovative medicines to patients and making them accessible HOUSTON, July 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage …
60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria
GlobeNewswire
·
July 17, 2025
Study will evaluate activity of tafenoquine against vector-borne pathogens, Borrelia (Lyme disease) and Bartonella in cell culture Borrelia and Bartonella, together with Babesia, represent the "3Bs," pathogens most often present in individuals with tick- …
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting
GlobeNewswire
·
July 17, 2025
SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company” or “BioAtla”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment …
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
GlobeNewswire
·
July 17, 2025
BASKING RIDGE, N.J. and SUBIACO, Australia, July 17, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid …
INVO Fertility Announces a 1:3 Reverse Stock Split Effective Pre-Market Opening on July 21, 2025
GlobeNewswire
·
July 17, 2025
SARASOTA, Fla., July 17, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO”) (NASDAQ: IVF), a healthcare company focused on the fertility market, announced today that it will effect a 1-for-3 reverse split of its issued and outstanding and authorized …
Hyperion DeFi to Host Corporate Update Event to Discuss Strategic Evolution from Eyenovia and the Future of On-Chain Finance on July 29, 2025
GlobeNewswire
·
July 17, 2025
LAGUNA HILLS, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) (“Hyperion DeFi” or the “Company”), today announced that it will host a special corporate update event on Tuesday, July 29, 2025 at 2:00 PM ET with CIO Hyunsu Jung …
Kestra Medical Technologies Wins 2025 Top Workplaces Industry Award, A National Recognition
GlobeNewswire
·
July 17, 2025
KIRKLAND, Wash., July 17, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, announced today that it is a 2025 Top Workplaces Industry winner by Energage, a purpose-driven …
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies
GlobeNewswire
·
July 17, 2025
The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The EMBOLD cohort 2 pivotal trial is on track for topline …
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
GlobeNewswire
·
July 17, 2025
LEXINGTON, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders …
KFSHRC Performs World’s First Robotic-Assisted BiVAD Implantation
GlobeNewswire
·
July 17, 2025
RIYADH, Saudi Arabia, July 17, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh has successfully performed the world’s first implantation of two artificial pumps for biventricular support (BiVAD-HMIII) using …
Peptides For Muscle Growth: How Oral Legal Peptides by Crazy Bulk Set New Benchmark For Bodybuilding Supplements and Muscle Building Results
GlobeNewswire
·
July 17, 2025
New York City, NY, July 17, 2025 (GLOBE NEWSWIRE) -- Introduction: Why Peptides for Muscle Growth Are Dominating the 2025 Supplement Scene As the demand for clean, high-performance muscle-building solutions rises, oral legal peptides are taking the fitness …
Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care
GlobeNewswire
·
July 17, 2025
WHO WHAT WHEN WHY Nuwellis, Inc. Termination of the REVERSE-HF clinical trial July 17, 2025 To redirect resources toward outpatient markets where scalable impact is highest. MINNEAPOLIS, July 17, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. today announced …
Repligen to Report Second Quarter 2025 Financial Results
GlobeNewswire
·
July 17, 2025
WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2025 financial results on Tuesday, July 29, 2025. The Company will issue a press release before the market …
Velocity Clinical Research Partners with Palantir to Solve Clinical Trials’ Payment Headache
GlobeNewswire
·
July 17, 2025
DURHAM, N.C., July 17, 2025 (GLOBE NEWSWIRE) -- Velocity Clinical Research (“Velocity”), the leading fully integrated site organization, has announced a strategic partnership with Palantir Technologies (“Palantir”) to automate and streamline the …
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline
GlobeNewswire
·
July 17, 2025
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet …
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company’s Strong Culture
GlobeNewswire
·
July 17, 2025
FRIENDSWOOD, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned multiple awards through the 2025 Top Workplaces …
Breckenridge Distillery Launches Mock One: Bold, Premium Non-Alcoholic Alternatives to Whiskey, Tequila, Gin & Rum - Crafted for Everyone Who Loves a Great Drink
GlobeNewswire
·
July 17, 2025
BRECKENRIDGE, Colo., July 17, 2025 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand by Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY), is pleased to announce the launch of Mock One, a new line of non- …
Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board
GlobeNewswire
·
July 17, 2025
Current Board member John Duke to succeed Jim Green as President …
BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes
GlobeNewswire
·
July 17, 2025
POMPANO BEACH, Fla., July 17, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, comments on the …